Medical oncologist Dr Philipp Ivanyi joined us at ESMO 2023 to share his thoughts on the latest precision oncology data to emerge from the congress and the possible impact on clinical practice. 

Clinical Takeaways

Cancer of unknown primary

  • CUPISCO: In patients with newly diagnosed, unfavourable, non-squamous CUP that responded to induction CTX, CGP with MGT improved PFS, thereby supporting a precision oncology approach in these patients
  • CUP-ONE: CTID molecular-expression classifier demonstrated similar performance overall to specialist C-IHC
  • Fudan CUP-001: Site-specific treatment guided by the approved 90-gene expression assay resulted in more therapy options, and significantly improved PFS with favourable OS vs empirical chemotherapy in patients with de novo CUP

Diagnostic

  • ARCAGEN: Molecular profiling of rare cancers identified many targetable alterations, and should be more routinely performed

Treatment

  • DESTINY-PanTumor01 (DPT-01): In heavily pretreated patients with limited treatment options, T-DXd demonstrated encouraging anticancer activity and long DoR across multiple tumour types with HER2m and a range of HER2 expression levels
  • LIBRETTO-531: First-line selpercatinib prolonged PFS, improved ORR, and achieved a better OS vs MKIs, and should now be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC

 

  • Help physicians translate the latest Precision Oncology data from ESMO 2023 into clinical practice.

Dr Ivanyi is the Assistant Medical Director Hematology, Oncology, Hemostasis, Stem Cell Transplantation (Palliative Care) at the Hanover Medical School. He is also Head of the Clinical Trial Unit for Medical Oncology

Dr Ivanyi also serves as:

  • Steering Committee and Spokesman, Immune Cooperative Oncology Group, Comporehensive Cancer Center, Claudia von Schelling Center (CCC-H)
  • Board Member, Clinical Trial Steering Committee, CCC-H
  • Spokesman Interdisciplinary Working Group Kidney Cancer, Germany Cancer Society (IAGN-DKG)

His research interests include clinical and experimental Research in Urogenital Cancer, Head and Neck Cancer, Sarcoma, Rare Cancers, Targeted Therapies. He has >80 SCI Publication and has a depth of experience in >50 Clinical Trials Phase I – IV (PI and Country Lead).

Dr Philipp Ivanyi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AIM, AIO, Apogepha, Astella, Astra Zeneca, Bayer, BMS, ClinSol, Deciphera, Deutsche Gesellschaft für Thoraxchirurgie, DKG-Onkoweb, EISAI, EMD-Serono, EUSA, FoFM, GSK, Id-Institut, Ipsen (Europe), Lilly, MedKom, Metaplan, MedWiss, Merck Serono (Global), MSD, MTE-Academy, New Concept Oncology, Niedersächsische Krebsgesellschaft, Novartis, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, Schmitz-Communikation, Solution Academy,Stiftung Immunonkologie, StreamedUP!, ThinkWired!, Vivantis and Wilhelm Sander Stiftung.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim
animated-video Animated Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.